Abstract
BRAF is a major oncoprotein and oncogenic mutations in BRAF are found in a significant number of cancers, including melanoma, thyroid cancer, colorectal cancer and others. Consequently, BRAF inhibitors have been developed as treatment options for cancers with BRAF mutations which have shown some success in improving patient outcomes in clinical trials. Development of resistance to BRAF kinase inhibitors is common, however, overcoming this resistance is an area of significant concern for clinicians, patients and researchers alike. In this review, we identify the mechanisms of BRAF kinase inhibitor resistance and discuss the implications for strategies to overcome this resistance in the context of new approaches such as multi-kinase targeted therapies and emerging RNA interference based technologies.
Keywords: BRAF, BRAF, gene therapy, kinase inhibitors, treatment resistance.
Current Cancer Drug Targets
Title:BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Volume: 14 Issue: 2
Author(s): Md Atiqur Rahman, Ali Salajegheh, Robert Anthony Smith and Alfred King-yin Lam
Affiliation:
Keywords: BRAF, BRAF, gene therapy, kinase inhibitors, treatment resistance.
Abstract: BRAF is a major oncoprotein and oncogenic mutations in BRAF are found in a significant number of cancers, including melanoma, thyroid cancer, colorectal cancer and others. Consequently, BRAF inhibitors have been developed as treatment options for cancers with BRAF mutations which have shown some success in improving patient outcomes in clinical trials. Development of resistance to BRAF kinase inhibitors is common, however, overcoming this resistance is an area of significant concern for clinicians, patients and researchers alike. In this review, we identify the mechanisms of BRAF kinase inhibitor resistance and discuss the implications for strategies to overcome this resistance in the context of new approaches such as multi-kinase targeted therapies and emerging RNA interference based technologies.
Export Options
About this article
Cite this article as:
Rahman Atiqur Md, Salajegheh Ali, Smith Anthony Robert and Lam King-yin Alfred, BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects, Current Cancer Drug Targets 2014; 14 (2) . https://dx.doi.org/10.2174/1568009614666140121150930
DOI https://dx.doi.org/10.2174/1568009614666140121150930 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging Studies in Hypercalcemia
Current Medicinal Chemistry Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design Sirtuins as Possible Drug Targets in Type 2 Diabetes
Current Drug Targets Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry A Multiwave Imaging Approach for Elastography
Current Medical Imaging Atom Based 3D-QSAR, Molecular Docking and Density Functional Theory Approaches to Identify Novel JNK-1 Inhibitor
Combinatorial Chemistry & High Throughput Screening Lactones: Generic Inhibitors of Enzymes?
Mini-Reviews in Medicinal Chemistry Gene Expression Profiling in Rodent Models for Schizophrenia
Current Neuropharmacology Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Docking: Successes and Challenges
Current Pharmaceutical Design Gender Disparity in Pediatric Diseases
Current Molecular Medicine A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015
Current Medicinal Chemistry Downregulation of CCKBR Expression Inhibits the Proliferation of Gastric Cancer Cells, Revealing a Potential Target for Immunotoxin Therapy
Current Cancer Drug Targets C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimers Disease
Current Alzheimer Research A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Preclinical Evaluation of In-111 and Ga-68 Labelled Minigastrin Analogues for CCK-2 Receptor Imaging
Current Radiopharmaceuticals Xenobiotic Nuclear Receptor-Mediated Regulation of UDP-Glucuronosyltransferases
Current Drug Metabolism Chemistry and Theranostic Applications of Radiolabeled Nanoparticles for Cardiovascular, Oncological, and Pulmonary Research
Current Topics in Medicinal Chemistry Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens
Current Drug Safety